Last reviewed · How we verify
non small cell lung cancer nsclc
Approved treatments
Clinical guidelines
- FDA label — neoadjuvant
Adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. - FDA label — neoadjuvant and adjuvant
Adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. - FDA label — 2L
Adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. - FDA label — adjuvant
TECENTRIQ is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. - FDA label — 1L
TECENTRIQ is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. - FDA label — 1L
TECENTRIQ is indicated in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. - FDA label — 1L
TECENTRIQ is indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. - FDA label — 2L
TECENTRIQ is indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. - FDA label — 1L
TECENTRIQ is indicated in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. - FDA label — 1L
TECENTRIQ is indicated for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- non small cell lung cancer nsclc patent landscape — cliff calendar, originator estates, attackable patents
- non small cell lung cancer nsclc treatment landscape brief
- non small cell lung cancer nsclc treatment updates RSS
Frequently asked questions about non small cell lung cancer nsclc
What are the treatment guidelines for non small cell lung cancer nsclc?
FDA label publishes guidelines for non small cell lung cancer nsclc. 10 guideline references tracked.
Related
- Treatment landscape: non small cell lung cancer nsclc patent cliff · non small cell lung cancer nsclc CI report
- All diseases: Browse the disease index · Disease landscape hub